Dantrolene must be available within 10 minutes of all anesthetizing locations to effectively manage malignant hyperthermia and reduce mortality.
Maintaining dantrolene within 10 min remains essential across anesthetizing locations including obstetrics; leaves open need for pregnancy-specific MH protocols.
( Anesthesiology . 2018;129:225–227) Malignant hyperthermia (MH) is unpredictable, rare, and has a high fatality rate. Fortunately, mortality related to MH has decreased in the past 3 decades, primarily because of increased availability of dantrolene and the education of operating room staff and anesthesia providers. The Malignant Hyperthermia Association of the United States has specified that dantrolene must be available within 10 minutes of all anesthetizing locations.
No takes yet. Share an insight, caveat, or question.
Cynthia A. Wong (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: